HIV / AIDS
Jan 21, 2023
HPTN 091 is a study assessing the feasibility, acceptability, preliminary impact of a multi-component strategy that provides HIV prevention services, gender-affirming hormone therapy, and Peer Health Navigation to improve pre-exposure prophylaxis (PrEP) uptake and...
Jan 20, 2023
The HPTN 094 randomized controlled trial tested whether delivering integrated health services for opioid use disorder (OUD) and HIV via mobile medical units with peer navigation was more effective than peer navigation alone to community agencies for people who inject...
Jan 19, 2023
HPTN 083 recruited HIV-uninfected men who have sex with men and transgender women at risk for acquiring HIV infection to evaluate the efficacy of the long-acting injectable agent, cabotegravir (CAB LA), for PrEP and demonstrated the superiority of cabotegravir for HIV...
Jan 17, 2023
HVTN 704/HPTN 085, or the AMP (Antibody Mediated Prevention) Study, is a five-year study testing the safety, tolerability, and prevention benefit of an experimental manufactured antibody (VRC01) against HIV. The study enrolled and followed 2,700 men and transgender...
Jan 16, 2023
Study of Heterologous Vaccine Regimen to prevent HIV-1 Infection among Cis-gender Men and Transgender Individuals who have Sex with Cis-gender Men and/or Transgender Individuals Web Links: https://clinicaltrials.gov/ct2/show/NCT03964415...
